Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of High Dose BAY A1040 CR (Nifedipine) in Essential Hypertension
NCT00768560Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2008
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nifedipine in essential hypertension (3 arms), sponsored by Bayer. Primary endpoint: Change of Sitting Blood Pressure at 2 weeks. Started Jan 2008; status: completed.
02
Drugs
nifedipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00768560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768560.